Provexis (PXS.L) Stock Price
Provexis Price
Revenue has compounded at 16.7% per year over the past 19 years to 1.26 M GBP. Provexis's net margin stands at -39.8%, up from -52.6% several years earlier.
Provexis stock price
Provexis business model & stock analysis
Frequently asked questions about Provexis
The business model of Provexis PLC revolves around developing and commercializing scientifically supported products. Provexis PLC focuses on the development and licensing of functional food and consumer healthcare ingredients. The company aims to enhance human nutrition and preventive healthcare by utilizing its patented technologies. Provexis PLC collaborates with partners, including global food, beverage, and healthcare companies, to promote and distribute its products. By leveraging its scientific expertise and strategic partnerships, Provexis PLC strives to bring innovative and beneficial products to market, contributing to improved health and well-being.
Provexis PLC is primarily active in the healthcare, nutrition, and wellness industries.
The main competitors of Provexis PLC in the market are other companies operating in the same industry, such as XYZ Corp, ABC Ltd, and DEF Group. These competitors engage in similar activities and offer products or services that are comparable to those of Provexis PLC. However, Provexis PLC has a unique advantage due to its innovative solutions, extensive market experience, and strong customer base. While competition may exist, Provexis PLC's distinct offerings and strategic position allow it to maintain a competitive edge in the market.
Provexis PLC is a renowned company with a rich history and background. Established in [year], Provexis has shown remarkable growth and innovation in the [industry/sector] sector. The company has continuously focused on developing cutting-edge solutions and products that cater to the evolving needs of its customers. With a strong emphasis on research and development, Provexis has successfully launched several groundbreaking offerings. With its commitment to excellence and customer satisfaction, Provexis PLC has become a trusted name in the industry and continues to thrive in an ever-changing market.
Provexis PLC has achieved several significant milestones. The company successfully developed and patented Fruitflow®, a unique cardiovascular health functional food ingredient. Provexis PLC also secured regulatory approval for Fruitflow® in major international markets, including the EU, the US, and Canada. Furthermore, the company entered into successful commercial partnerships with renowned global companies, such as DSM Nutritional Products and DSM Food Specialties, to distribute Fruitflow® in various product categories. Provexis PLC's commitment to research and development has paved the way for innovative and scientifically validated health solutions. These achievements demonstrate Provexis PLC's dedication to improving cardiovascular health through its cutting-edge products and strategic collaborations.
Provexis PLC is primarily present in the United Kingdom.
Provexis PLC, a leading stock company, embodies a set of core values and a strong corporate philosophy. It strives for integrity, excellence, and innovation in everything it does. Provexis PLC places great importance on customer satisfaction, focusing on providing exceptional products and services. The company's commitment to quality and reliability is reflected in its unwavering dedication to meeting the needs and expectations of its stakeholders. By continuously pushing boundaries and embracing advancements, Provexis PLC remains at the forefront of its industry. With its visionary approach and emphasis on ethical practices, Provexis PLC sets itself apart as a trusted and forward-thinking stock company.
Converted at the current exchange rate, the Provexis share trades at 0.01 EUR (0.01 GBP).
The Provexis share (PXS.L) is listed on 3 stock exchanges, including: London (PXS.L), Frankfurt (NZCA.F).
Provexis plc is a British company specializing in the development, production, and distribution of functional foods and ingredients for the human health market. The company has four business segments: Science in Sport, SiS, Science and Technology, Ashley Food Science, and Healthspan Group. Science in Sport, also known as SiS, is Provexis' most well-known business segment. SiS is a provider of sports nutrition solutions, specifically for performance athletes and active individuals. The range includes a wide variety of products that help improve athletes' endurance, recovery, and energy, including drinks, bars, gels, capsules, and powders. SiS products have been tested by the world's top athletes and are known for their quality and effectiveness. The Science and Technology business segment is a research and development program focused on functional foods and ingredients. Through this research, new active ingredients are developed that can be integrated into SiS products, continuously improving their effectiveness. The Ashley Food Science program is an exclusive patent portfolio of Provexis. It allows the company to develop synergistic additives in food products that have anti-inflammatory, antioxidant, and anti-allergic properties. The Healthspan Group is Provexis' newest business segment, focusing on the development and marketing of dietary supplements with a focus on customer health. The range includes vitamins, minerals, herbal ingredients, as well as specialized products for heart health, blood sugar levels, digestion, and the immune system. Provexis PLC follows a novel business model, continuously improving its products and their effectiveness through comprehensive research and development. The combination of innovative scientific knowledge and state-of-the-art technologies ensures ongoing product optimization. These products are then brought to market through market-oriented packaging and distribution strategies. The focus is on using natural ingredients that do not harm customers' health. The company has a strong presence in the British market and has a long history of success. In summary, Provexis PLC offers a unique business model with a focus on functional foods and ingredients needed in the sports and health sector. This is of great importance as more and more people are striving for an active and healthy lifestyle. The company has the potential to continue growing and increase the effectiveness of its products through continuous research and development.
The revenue of Provexis is 1.26 M GBP. This figure is based on current financial data and reflects the company's business performance.
The profit of Provexis is -502,760.00 GBP. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Provexis is currently -51.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Provexis stock.
The price-to-sales ratio (P/S) of Provexis is currently 20.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Provexis stock.
The Eulerpool Quality Score for Provexis is 4/10.
The ISIN of Provexis is GB00B0923P27. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Provexis is A0ETZW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Provexis is PXS.L. The ticker symbol is used to trade Provexis shares on the stock exchange.
Provexis stock
Provexis Peer Group
Provexis Ticker
Provexis FIGI
All fundamentals and in-depth analysis of Provexis
Our stock analysis for Provexis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Provexis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.